Table 4

Impact of HY-score at 3 months post-HCT on clinical outcomes in multivariate analyses

HY score*cGVHDNRMRelapseOS
HR† (95% CI)PHR† (95% CI)PHR† (95% CI)PHR† (95% CI)P
As a continuous variable 1.37 (1.19-1.59) <.0001 1.66 (1.17-2.35) .0043 0.83 (0.66-1.04) .11 1.11 (0.94-1.31) .2 
As a group variable         
 0 1 Ref. 1 Ref. 1 Ref. 1 Ref. 
 1 1.11 (0.55-2.24) .77 0.73 (0.09-5.96) .77 0.97 (0.45-2.09) .94 0.92 (0.40-2.11) .85 
 2-3 2.19 (1.17-4.11) .014 13.4 (1.99-89.7) .0076 0.42 (0.17-1.02) .06 0.62 (0.24-1.62) .33 
 4-6 5.00 (2.30-10.9) <.0001 20.0 (2.70-148) .0034 0.56 (0.18-1.73) .32 1.78 (0.79-4.01) .16 
HY score*cGVHDNRMRelapseOS
HR† (95% CI)PHR† (95% CI)PHR† (95% CI)PHR† (95% CI)P
As a continuous variable 1.37 (1.19-1.59) <.0001 1.66 (1.17-2.35) .0043 0.83 (0.66-1.04) .11 1.11 (0.94-1.31) .2 
As a group variable         
 0 1 Ref. 1 Ref. 1 Ref. 1 Ref. 
 1 1.11 (0.55-2.24) .77 0.73 (0.09-5.96) .77 0.97 (0.45-2.09) .94 0.92 (0.40-2.11) .85 
 2-3 2.19 (1.17-4.11) .014 13.4 (1.99-89.7) .0076 0.42 (0.17-1.02) .06 0.62 (0.24-1.62) .33 
 4-6 5.00 (2.30-10.9) <.0001 20.0 (2.70-148) .0034 0.56 (0.18-1.73) .32 1.78 (0.79-4.01) .16 

Ref., reference.

*

HY score is the cumulative number of HY-Abs detected 3 mo post-HCT.

†

HRs are shown after adjusting for age of patient and donor, disease, disease risk, CMV serostatus, donor types, cell sources, usage of total body irradiation, usage of anti-thymocyte globulin, and grade of aGVHD.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal